Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients with Polycythemia Vera

Phase 3 RESPONSE study 5-year follow-up results demonstrate that clinical benefit, including clinicohematologic response and hematocrit control, is durable with long-term ruxolitinib therapy among patients with hydroxyurea-resistant/intolerant polycythemia vera. 

 Blood (ASH Abstract)

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.